Literature DB >> 18382647

An Outbreak of Human Coronavirus OC43 Infection and Serological Cross-reactivity with SARS Coronavirus.

David M Patrick1, Martin Petric, Danuta M Skowronski, Roland Guasparini, Timothy F Booth, Mel Krajden, Patrick McGeer, Nathalie Bastien, Larry Gustafson, Janet Dubord, Diane Macdonald, Samara T David, Leila F Srour, Robert Parker, Anton Andonov, Judith Isaac-Renton, Nadine Loewen, Gail McNabb, Alan McNabb, Swee-Han Goh, Scott Henwick, Caroline Astell, Jian Ping Guo, Michael Drebot, Raymond Tellier, Francis Plummer, Robert C Brunham.   

Abstract

BACKGROUND: In summer 2003, a respiratory outbreak was investigated in British Columbia, during which nucleic acid tests and serology unexpectedly indicated reactivity for severe acute respiratory syndrome coronavirus (SARS-CoV).
METHODS: Cases at a care facility were epidemiologically characterized and sequentially investigated for conventional agents of respiratory infection, SARS-CoV and other human CoVs. Serological cross-reactivity between SARS-CoV and human CoV-OC43 (HCoV-OC43) was investigated by peptide spot assay.
RESULTS: Ninety-five of 142 residents (67%) and 53 of 160 staff members (33%) experienced symptoms of respiratory infection. Symptomatic residents experienced cough (66%), fever (21%) and pneumonia (12%). Eight residents died, six with pneumonia. No staff members developed pneumonia. Findings on reverse transcriptase-polymerase chain reaction assays for SARS-CoV at a national reference laboratory were suspected to represent false positives, but this was confounded by concurrent identification of antibody to N protein on serology. Subsequent testing by reverse transcriptase-polymerase chain reaction confirmed HCoV-OC43 infection. Convalescent serology ruled out SARS. Notably, sera demonstrated cross-reactivity against nucleocapsid peptide sequences common to HCoV-OC43 and SARS-CoV.
CONCLUSIONS: These findings underscore the virulence of human CoV-OC43 in elderly populations and confirm that cross-reactivity to antibody against nucleocapsid proteins from these viruses must be considered when interpreting serological tests for SARS-CoV.

Entities:  

Keywords:  Coronavirus; Human coronavirus OC43; Outbreak; Respiratory infection; SARS coronavirus; SARS-CoV; Severe acute respiratory syndrome

Year:  2006        PMID: 18382647      PMCID: PMC2095096          DOI: 10.1155/2006/152612

Source DB:  PubMed          Journal:  Can J Infect Dis Med Microbiol        ISSN: 1712-9532            Impact factor:   2.471


  28 in total

Review 1.  The severe acute respiratory syndrome.

Authors:  Joseph S M Peiris; Kwok Y Yuen; Albert D M E Osterhaus; Klaus Stöhr
Journal:  N Engl J Med       Date:  2003-12-18       Impact factor: 91.245

2.  Infectious diseases. Unexplained false alarm may hold lessons.

Authors:  Martin Enserink
Journal:  Science       Date:  2003-10-31       Impact factor: 47.728

3.  Profiles of IgG antibodies to nucleocapsid and spike proteins of the SARS-associated coronavirus in SARS patients.

Authors:  Yanbin Wang; Zhaorui Chang; Jing Ouyang; Haiyan Wei; Renquan Yang; Yangong Chao; Jianguo Qu; Jianwei Wang; Tao Hung
Journal:  DNA Cell Biol       Date:  2005-08       Impact factor: 3.311

4.  Human coronavirus OC43 causes influenza-like illness in residents and staff of aged-care facilities in Melbourne, Australia.

Authors:  C J Birch; H J Clothier; A Seccull; T Tran; M C Catton; S B Lambert; J D Druce
Journal:  Epidemiol Infect       Date:  2005-04       Impact factor: 2.451

5.  Prevalence of IgG antibody to SARS-associated coronavirus in animal traders--Guangdong Province, China, 2003.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2003-10-17       Impact factor: 17.586

6.  Investigation of a nosocomial outbreak of severe acute respiratory syndrome (SARS) in Toronto, Canada.

Authors:  Monali Varia; Samantha Wilson; Shelly Sarwal; Allison McGeer; Effie Gournis; Eleni Galanis; Bonnie Henry
Journal:  CMAJ       Date:  2003-08-19       Impact factor: 8.262

7.  Antigenic cross-reactivity between severe acute respiratory syndrome-associated coronavirus and human coronaviruses 229E and OC43.

Authors:  Xiao-Yan Che; Li-Wen Qiu; Zhi-Yong Liao; Ya-di Wang; Kun Wen; Yu-Xian Pan; Wei Hao; Ya-Bo Mei; Vincent C C Cheng; Kwok-Yung Yuen
Journal:  J Infect Dis       Date:  2005-05-06       Impact factor: 5.226

8.  Comparison of 9 different PCR primers for the rapid detection of severe acute respiratory syndrome coronavirus using 2 RNA extraction methods.

Authors:  Linda Chui; Michael Drebot; Anton Andonov; Astrid Petrich; Martin Glushek; James Mahony
Journal:  Diagn Microbiol Infect Dis       Date:  2005-09       Impact factor: 2.803

9.  Comprehensive detection and identification of human coronaviruses, including the SARS-associated coronavirus, with a single RT-PCR assay.

Authors:  D Adachi; G Johnson; R Draker; M Ayers; T Mazzulli; P J Talbot; R Tellier
Journal:  J Virol Methods       Date:  2004-12-01       Impact factor: 2.014

10.  SARS corona virus peptides recognized by antibodies in the sera of convalescent cases.

Authors:  Jian-Ping Guo; Martin Petric; William Campbell; Patrick L McGeer
Journal:  Virology       Date:  2004-07-01       Impact factor: 3.616

View more
  65 in total

1.  Molecular determinants of severe acute respiratory syndrome coronavirus pathogenesis and virulence in young and aged mouse models of human disease.

Authors:  Matthew Frieman; Boyd Yount; Sudhakar Agnihothram; Carly Page; Eric Donaldson; Anjeanette Roberts; Leatrice Vogel; Becky Woodruff; Diana Scorpio; Kanta Subbarao; Ralph S Baric
Journal:  J Virol       Date:  2011-11-09       Impact factor: 5.103

2.  Guidelines for the management of adult lower respiratory tract infections--full version.

Authors:  M Woodhead; F Blasi; S Ewig; J Garau; G Huchon; M Ieven; A Ortqvist; T Schaberg; A Torres; G van der Heijden; R Read; T J M Verheij
Journal:  Clin Microbiol Infect       Date:  2011-11       Impact factor: 8.067

Review 3.  Mechanisms of severe acute respiratory syndrome pathogenesis and innate immunomodulation.

Authors:  Matthew Frieman; Ralph Baric
Journal:  Microbiol Mol Biol Rev       Date:  2008-12       Impact factor: 11.056

4.  Recommendations for use of the diverse tests for detection of SARS-COV-2 infection.

Authors:  Lidia Gestoso-Pecellín; Yuneysa García-Flores; Pino González-Quintana; José Luis Marrero-Arencibia
Journal:  Enferm Clin       Date:  2020-10-14

5.  Molecular epidemiology of human coronavirus OC43 reveals evolution of different genotypes over time and recent emergence of a novel genotype due to natural recombination.

Authors:  Susanna K P Lau; Paul Lee; Alan K L Tsang; Cyril C Y Yip; Herman Tse; Rodney A Lee; Lok-Yee So; Yu-Lung Lau; Kwok-Hung Chan; Patrick C Y Woo; Kwok-Yung Yuen
Journal:  J Virol       Date:  2011-08-17       Impact factor: 5.103

6.  Systematic assembly of a full-length infectious clone of human coronavirus NL63.

Authors:  Eric F Donaldson; Boyd Yount; Amy C Sims; Susan Burkett; Raymond J Pickles; Ralph S Baric
Journal:  J Virol       Date:  2008-09-25       Impact factor: 5.103

Review 7.  Recombination, reservoirs, and the modular spike: mechanisms of coronavirus cross-species transmission.

Authors:  Rachel L Graham; Ralph S Baric
Journal:  J Virol       Date:  2009-11-11       Impact factor: 5.103

8.  Human coronavirus OC43 nucleocapsid protein binds microRNA 9 and potentiates NF-κB activation.

Authors:  Frances W Lai; Kyle B Stephenson; James Mahony; Brian D Lichty
Journal:  J Virol       Date:  2013-10-09       Impact factor: 5.103

9.  Development of a nucleocapsid-based human coronavirus immunoassay and estimates of individuals exposed to coronavirus in a U.S. metropolitan population.

Authors:  Emily G Severance; Ioannis Bossis; Faith B Dickerson; Cassie R Stallings; Andrea E Origoni; Anne Sullens; Robert H Yolken; Raphael P Viscidi
Journal:  Clin Vaccine Immunol       Date:  2008-10-22

Review 10.  Host-pathogen interactions during coronavirus infection of primary alveolar epithelial cells.

Authors:  Tanya A Miura; Kathryn V Holmes
Journal:  J Leukoc Biol       Date:  2009-07-28       Impact factor: 4.962

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.